Intron Health - Marinomed Biotech - INITIATION: Fighting COVID With Seaweed (TP EUR 160, 33% Upside)
Marinomed is an Austrian biotech that IPO’d last year and already generates ~€6m of revenue per year from its Carragelose division, which sells six OTC products for cough, cold & flu through partners. Carragelose’s revolutionary approach to treating respiratory diseases means it is likely to be effective in COVID, with a company-sponsored trial expected to read out in Q221. Meanwhile, the Marinosolv platform, which solubilises older, proven drugs to improve performance, is advancing three clinical assets, the first of which could launch in 2022. With a cash runway to end 2022, they are in a strong position to license the first asset, Budesolv, which already has positive phase 3 data in allergic rhinitis, a market where the top 5 brands sell >$2bn/year. For access to the initiation, please contact
Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.
New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:
- Pan European Telecom Services and Cable
- US Telecoms, Cable, Satellite and Towers
- Global Emerging Market Telecoms
- Japan Telecoms
- Asian Internet
- Pan European Healthcare
- Global healthcare thematic research
We provide debt research on:
- Pan European Telecom Services and Cable
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.